Evidence map›Paper›PMID 29566041›Full record

ArticlePloS one2018

Rats deficient C-type natriuretic peptide suffer from impaired skeletal growth without early death.

Toshihito Fujii, Keisho Hirota, Akihiro Yasoda, Akiko Takizawa, Naomi Morozumi, Ryuichi Nakamura, Takafumi Yotsumoto, Eri Kondo, Yui Yamashita, Yoriko Sakane and 12 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. The Natriuretic Peptides for Hypertension Treatment.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2022
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 2 countries.

Toshihito FujiiDepartment of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Keisho HirotaDepartment of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Akihiro YasodaDepartment of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.ORCID 0000-0001-8866-5303
Akiko TakizawaDepartment of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America.
Naomi MorozumiAsubio Pharma Co., Ltd., Kobe, Japan.
Ryuichi NakamuraAsubio Pharma Co., Ltd., Kobe, Japan.
Takafumi YotsumotoAsubio Pharma Co., Ltd., Kobe, Japan.
Eri KondoDepartment of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Yui YamashitaDepartment of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Yoriko SakaneDepartment of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Yugo KanaiDepartment of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Yohei UedaDepartment of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Ichiro YamauchiDepartment of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Shigeki YamanakaDepartment of Maxillofacial Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Kazumasa NakaoDepartment of Maxillofacial Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Koichiro KuwaharaDepartment of Cardiovascular Medicine, Shinshu University Graduate School of Medicine, Matsumoto, Japan.
Toshimasa JindoAsubio Pharma Co., Ltd., Kobe, Japan.
Mayumi FuruyaAsubio Pharma Co., Ltd., Kobe, Japan.
Tomoji MashimoGenome Editing Research and Development (R&D) Center and Institute of Experimental Animal Sciences, Graduate School of Medicine, Osaka University, Osaka, Japan.
Nobuya InagakiDepartment of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Tadao SerikawaLaboratory of Pharmacology, Osaka University of Pharmaceutical Sciences, Takatsuki, Japan.
Kazuwa NakaoMedical Innovation Center, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Kyoto University · JPKobe Asahi Hospital · JPMedical College of Wisconsin · USOsaka University of Pharmaceutical Sciences · JPShinshu University · JPThe University of Osaka · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have previously investigated the physiological role of C-type natriuretic peptide (CNP) on endochondral bone growth, mainly with mutant mouse models deficient in CNP, and reported that CNP is indispensable for physiological endochondral bone growth in mice. However, the survival rate of CNP knockout (KO) mice fell to as low as about 70% until 10 weeks after birth, and we could not sufficiently analyze the phenotype at the adult stage. Herein, we generated CNP KO rats by using zinc-finger nuclease-mediated genome editing technology. We established two lines of mutant rats completely deficient in CNP (CNP KO rats) that exhibited a phenotype identical to that observed in mice deficient in CNP, namely, a short stature with severely impaired endochondral bone growth. Histological analysis revealed that the width of the growth plate, especially that of the hypertrophic chondrocyte layer, was markedly lower and the proliferation of growth plate chondrocytes tended to be reduced in CNP KO rats. Notably, CNP KO rats did not have malocclusions and survived for over one year after birth. At 33 weeks of age, CNP KO rats persisted significantly shorter than wild-type rats, with closed growth plates of the femur in all samples, which were not observed in wild-type rats. Histologically, CNP deficiency affected only bones among all body tissues studied. Thus, CNP KO rats survive over one year, and exhibit a deficit in endochondral bone growth and growth retardation throughout life.

Indexed as

AnimalsBone DevelopmentBone Diseases, DevelopmentalDwarfismFemaleGene DeletionGene Knockout TechniquesGrowth PlateNatriuretic Peptide, C-TypeOsteogenesisRatsRats, Inbred F344Rats, TransgenicNatriuretic Peptide, C-Type

Identifiers

PMID29566041
PMCPMC5864047
OpenAlexW2793166654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.